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Efforts to identify lupus-associated causal variants in the FAM167A/BLK locus on 8p21 are hampered by highly associated noncausal
variants. In this report, we used a trans-population mapping and sequencing strategy to identify a common variant (rs922483) in the
proximal BLK promoter and a tri-allelic variant (rs1382568) in the upstream alternative BLK promoter as putative causal variants for
association with systemic lupus erythematosus. The risk allele (T) at rs922483 reduced proximal promoter activity and modulated alter-
native promoter usage. Allelic differences at rs1382568 resulted in altered promoter activity in B progenitor cell lines. Thus, our results
demonstrated that both lupus-associated functional variants contribute to the autoimmune disease association bymodulating transcrip-
tion of BLK in B cells and thus potentially altering immune responses.Introduction
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Table 1. Demographics of SLE Populations Studied
Ancestry
Affected Individuals Control Individuals
Male Female Total Male Female Total
European 344 3,617 3,980 1,181 2,365 3,546
African American 109 1,297 1,406 5,45 1,189 1,734
East Asian 101 1,171 1,272 1,158 1,112 1,270sclerosis (MIM 181750), rheumatoid arthritis (MIM
180300) and Sjo¨gren’s syndrome (MIM 270150).4–11 Ana-
lyses of expression in transformed B cell lines demonstrate
that risk-conferring variants within FAM167A (MIM
610085) and BLK are associated with altered mRNA expres-
sion of both FAM167A and BLK; however, the causal alleles
and mechanisms remain undefined.7
Like other genes with TATA-less promoters, the genomic
DNA upstream of exon 1 of BLK has two transcription start
sites and promoters that drive BLK transcription: a ubiqui-
tous proximal promoter (P1) and a B-lymphocyte-specific
promoter (P2).1 Recent evidence suggests that immature
B cells from individuals carrying lupus risk alleles have
lower amounts of BLK than such cells from individuals
without lupus risk alleles.12
In this study, we leveraged the difference in linkage
disequilibrium (LD) structure across populations to
examine the FAM167A/BLK locus in a multiethnic popula-
tion of SLE cases and controls and then used focused rese-
quencing to identify additional lupus-associated variants.
Functional assessment revealed the molecular mechanism
impacted by the variant alleles. Using this approach, we
successfully identified two functional variants that regu-
late transcription from the promoters in a cell-type- and
developmental-stage-specific fashion.Subjects and Methods
Study Subjects
Approval by the institutional review boards of the Oklahoma
Medical Research Foundation and the collaborators’ institutions
was obtained prior to sample collection. All study participants
provided written consent at the time of sample collection. De-
identified genomic DNA samples from individuals with SLE and
control subjects were analyzed from 6,658 unrelated individuals
(3,980 individuals of European ancestry [EA], 1,272 of Asian
ancestry [AS], and 1,406 of African American ancestry [AA]) and
6,550 unrelated controls (3,546 EA, 1,270 of AS, and 1,734 AA)
(Table 1). These samples were obtained through the Lupus
Family Registry and Repository (LFRR) as part of the Oklahoma
Rheumatic Disease Research and Cores Center (ORDRCC) and
through collaborators from 24 additional study sites. Collabora-
tors and the sources of all case and control individuals used in
these studies are shown in Table S1 in the Supplemental Data
available online.
For resequencing experiments, deidentified genomic DNA
samples from individuals with SLE and controls were obtained
from the Autoimmune Biomarkers Collaborative NetworkThe Am(ABCoN) of the New York Cancer Project (NYCP) (191 EA SLE
individuals and 96 EA controls) courtesy of Dr. Gregersen for
the discovery cohort (Table S2). All individuals with SLE met
classification criteria13 (American College of Rheumatology). All
samples were independent. Only one randomly selected SLE sam-
ple was included if multiple affected individuals were available
from a multiplex lupus pedigree. DNA was obtained from blood
samples.Genotyping and Quality Control
All samples were genotyped as a part of a joint effort of more than
40 investigators from around the world. These investigators
contributed samples, funding, and hypotheses used for designing
a custom, highly multiplexed Illumina-bead-based array method
on a BeadStation system.14 Select SNPs were also assayed for geno-
type confirmation via TaqMan methods (Applied Biosystems).
Genotyping facilities are located at the Oklahoma Medical
Research Foundation, and data were sent to a central data center
at Wake Forest Medical Center for quality control. These data
were then distributed back to the investigators who had requested
specific SNPs for final analysis and publication.
Genotype data were only used from samples with a call rate
greater than 90% of the SNPs screened (98.05% of the samples).
For analyses, only genotype data from SNPs with a call frequency
greater than 90% in the samples tested and an Illumina Gen-
Train score greater than 0.7 (96.74% of all SNPs screened) were
used. In addition, at least one previously genotyped sample
was randomly placed on each assay plate and used for tracking
samples through the genotyping process. More information on
Illumina genotyping can be found at the Illumina website
(Web Resources section).Correction for Population Stratification
Following best practices in genome-wide association studies, we
used all of the genotype data from all SNPs that passed quality con-
trol, including the published set of ancestry-informative makers
(AIMs),15 and computed the principal components and admixture
estimates. Regions of known extended LD were removed. The
combination of 12,000 SNPs, including published sets of AIMs
and the principal-component analysis computed across all ethnic-
ities, generated principal components that separated ethnicities.
To minimize the inflation of the test statistics, we included popu-
lation-specific principal components in the logistic regression
models as covariates.15,16 Population clustering based upon the
three-dimensional plot of principal component 1 (PC1), PC2,
and PC3 of the final samples used in these studies is presented
(Figure S1).Imputation-Based Association Analysis
Initially, we genotyped 372 SNPs within the FAM167A/BLK region
(11,033,737–11,618,107 bp, hg19), and after performing quality
control (HWE > 0.001 in controls and minor allele frequency
[MAF] > 0.01), we had 329 SNPs in AA samples, 259 SNPs in EA
samples, and 201 SNPs in AS available for imputation. To investi-
gate the new variants in the FAM167A/BLK region, we used the
1000 Genomes project17 as a reference panel for imputation to
estimate missing genotypes. After quality control measures
(HWE> 0.001 in controls andMAF> 0.01) for the 1000 Genomes
project reference panel, which contains 11,528 SNPs within the
FAM167A/BLK region, we used 246 AA samples with 4,813 SNPs,
381 EA samples with 2,508 SNPs, and 286 AS samples witherican Journal of Human Genetics 94, 586–598, April 3, 2014 587
1,847 SNPs for imputation. Imputation was carried out with
MACH,17,18 which provided a quantitative assessment of estimate
uncertainty (Rsq). All imputed SNPs were filtered with the quality
controls (HWE > 0.001, MAF > 0.01, and Rsq > 0.6), and 2,137
SNPs in AA samples, 1,199 SNPs in EA samples, and 738 SNPs in
AS samples were used for further analysis. At each SNP, p value,
odds ratio (OR), and 95% confidence interval (CI) were calculated
with gPLINK.19 We calculated allelic association results (Table 2
and Table S3) to account for imputation uncertainty with mach2
dat;20 genotyped and imputed SNPs with p values % 0.05 from
at least one population are shown.
For each ethnic population, we used WHAP19 to calculate pair-
wise conditional analysis for each pair of SNPs (the most signifi-
cant SNP plus each other SNP) and identify the independent
effects for each SNP. We assessed whether the joint effect is
explained by a single SNP. If a haplotype was significant and
remained significant after we conditioned on a SNP, then that
SNP did not independently account for the association. However,
if the p value was no longer significant after we conditioned on a
SNP, then we considered that SNP to be the source of the
association.
Resequencing of FAM167A/BLK Exons and the
Upstream Promoter Region
Resequencing was performed on 191 individuals with SLE and 96
controls from ABCoN, as detailed above (Table S2). All 13 exons
and the 2.5 kb upstream promoter sequence were resequenced
with whole-genome amplified genomic DNA (Cat#150045,
QIAGEN). Primers for resequencing were designed to target the
13 exon regions and 2.5 kb upstream promoter region. PCR ampli-
fication was performed on genomic DNA via high-fidelity Taq
polymerase according to standard protocols. PCR product purity
and size were assessed on 2% agarose gels. Sanger sequencing
was performed per themanufacture’s protocol. Sequence trace files
were manually analyzed for variations.
Haplotype Analysis
We used the expectation-maximization algorithm in the WHAP
program19 to estimate haplotype frequencies. WHAP directly
calculates likelihood estimates, likelihood ratios, and p values
by taking into account the information loss due to haplotype-
phase uncertainty and missing genotypes. Association between
inferred haplotypes and SLE was tested with an omnibus test.
We used both conditional analysis and global haplotype analysis
to disentangle the correlation structure in which SNPs are truly
associated with phenotype. To test which of the associated
SNPs were causal and which were significantly associated by
LD, we performed haplotype conditional analysis on each SNP.
If the global haplotype association disappeared, then the specific
SNP on which we had conditioned accounted for the whole
association.
Nuclear Extract Preparation
Nuclear extracts from the human Jurkat T cell line, RS4;11 pro-B
cell line, Nalm-6 and Reh pre-B cell lines, Ramos immature B cell
line, and Daudi mature B cell line (American Type Tissue Culture
Collection) were obtained. Cells were maintained in RPMI with
10% heat-inactivated fetal bovine serum, L-glutamine (2 mM),
and penicillin and streptomycin (100 units/ml). Nuclear protein
extracts were prepared from cells, dialyzed against a buffer
composed of 20 mM HEPES, 20% glycerol, 0.1M potassium chlo-588 The American Journal of Human Genetics 94, 586–598, April 3, 2ride, and 0.2 mM EDTA (pH 7.9), and used in nuclear binding
assays (Figures S2 and S3).21
Electrophoretic Mobility-Shift Assay
A forward and reverse 21 base pair synthetic oligonucleotide from
the BLK promoter flanking the rs922483 polymorphism was pur-
chased from Integrated DNATechnologies. All oligos were purified
with polyacrylamide gel electrophoresis. Probes carrying the risk
allele (T) and nonrisk allele (C) were generated, and pairs of one
forward and one reverse oligonucleotide were mixed in equal
molar ratios, heated, and then allowed to anneal to generate
the 21 bp, double-stranded probes. T4 polynucleotide kinase
(Invitrogen) was used for labeling the end of each DNA probe
with (g-32P) adenosine triphosphate (Amersham). The nuclear ex-
tracts prepared as discussed above were incubated for 25 min at
37C with labeled probes in binding buffer (1 mg poly(dI-dC),
20 mM HEPES, 10% glycerol, 100 mM KCl, and 0.2 mM EDTA
[pH 7.9]). DNA-protein complexes were resolved on denaturing
5% acrylamide gels. For supershift assays, varying concentrations
of anti-pol II antibody (clone 8A7 and clone H-224, Santa Cruz)
were added to the DNA-protein complexes; this was followed by
incubation for 15 min prior to resolution on denaturing 5% acryl-
amide gels (Figure S3).
Luciferase Reporter Assay
We amplified the upstream sequence (2,256 toþ55 bp) of BLK by
using genomic DNA from individuals with nonrisk haplotypes.
PCR products were cloned into pCR2.1-TOPO vector (Invitrogen,
Cat# K4500-01) and subcloned into pGL4 luciferase reporter vec-
tors (Promega, Cat# E6651, Madison, WI). The construct carrying
the nonrisk haplotype was used as a template for mutagenesis
(Stratagene) to create other allelic haplotypes.
An internal control reporter vector, pRL-TK, containing Renilla
luciferase driven by the thymidine kinase promoter was simulta-
neously transfected with our experimental vectors as a control
for assay-to-assay variability. The Renilla luciferase activity ex-
pressed by the internal control vector was used for normalization
of transfection efficiency. One to 5 mg of each vector was trans-
fected into the Jurkat (1 3 106/sample in triplicate), RS4;11 (2 3
106/sample in triplicate), Nalm-6 (3 3 106/sample in triplicate),
Ramos (3 3 106/sample in triplicate), and Daudi (5 3 106/sample
in triplicate) cell lines. Cells were then incubated at 37C for 16 hr.
Luciferase activity wasmeasuredwith the Dual-Luciferase Reporter
Assay System (Promega, Cat# E1960). Luciferase activity was
normalized through division of BLK risk or nonrisk construct re-
porter activity by the reporter activity of the pRL-TK construct.
The mean and standard error of measurement were calculated
on the basis of the normalized luciferase activities and used for
further analysis.Results
Trans-Population Association Testing Identified
rs922483 as the Predominant SLE-Associated Causal
Variant
To identify the causal variants responsible for the associa-
tion of FAM167A/BLK with SLE, we genotyped 372
SNPs selected from the phase II HapMap in the region
spanning 584.37 kb (11,033,737–11,618,107 bp, hg19) in
chromosomal region 8p21 in three ethnic populations.014
Table 2. Association- and Conditional-Analysis Results for Significantly Associated Peak Genotyped and Imputed SNPs
Chr. dsSNP
BP
(build37)
Allele1/
Allele2
European Americana Asianb African Americanc
Freq_
Allele1
(Case/
Control)d eAdj. p
OR
(95% CI)
r2
Peak
fpcond on
rs998683
Freq_
Allele1
(Case/
Control) Adj. p
OR
(95% CI)
r2
Peak
pcond on
rs1478901
Freq_
Allele1
(Case/
Control) Adj. p
OR
(95% CI)
r2
Peak
pcond on
rs2736345
pcond on
rs922483
8 rs2409780 11,337,587 T/C 0.699/
0.752
3.20 3
1013
0.77 (0.71–
0.82)
0.93 0.97 0.189/
0.267
2.10 3
1011
0.64 (0.56–
0.73)
0.85 0.29 0.822/
0.865
3.913 3
1006
0.73 (0.63–
0.83)
0.474 0.020 0.100
8 rs1564267g 11,337,887 A/G 0.154/
0.167
3.54 3
1002
0.91 (0.83–1) 0.08 0.91 0.166/
0.237
3.11 3
1010
0.64 (0.56–
0.74)
0.72 0.38 0.429/
0.462
0.01079 0.88 (0.8–
0.97)
0.070 0.127 0.353
8 rs2618444 11,338,370 A/C 0.699/
0.752
3.06 3
1013
0.77 (0.71–
0.82)
0.93 0.97 0.189/
0.267
2.30 3
1011
0.64 (0.56–
0.73)
0.85 0.29 0.823/
0.865
0.00000411 0.73 (0.63–
0.84)
0.475 0.019 0.095
8 rs62489069 11,338,383 A/G 0.67/0.72 1.81 3
1011
0.79 (0.73–
0.85)
0.80 0.97 0.168/
0.238
3.82 3
1010
0.64 (0.56–
0.74)
0.72 0.36 0.752/
0.791
0.000237 0.8 (0.71–
0.9)
0.238 0.061 0.166
8 rs35393613 11,338,466 C/T 0.67/0.72 1.78 3
1011
0.79 (0.73–
0.85)
0.80 0.96 0.168/
0.238
5.26 3
1010
0.64 (0.56–
0.74)
0.72 0.40 0.776/
0.813
0.0004116 0.8 (0.71–
0.91)
0.289 0.068 0.184
8 rs1531577 11,338,561 T/C 0.712/
0.694
1.49 3
1002
1.09 (1.02–
1.17)
0.16 0.57 0.835/
0.766
3.50 3
1010
1.56 (1.35–
1.8)
0.73 0.29 0.834/
0.805
0.004446 1.2 (1.06–
1.37)
0.077 0.343 0.150
8 rs2061831 11,339,882 T/C 0.699/
0.752
2.42 3
1013
0.76 (0.71–
0.82)
0.94 0.87 0.188/
0.265
5.40 3
1011
0.64 (0.56–
0.74)
0.87 0.26 0.823/
0.865
4.401 3
1006
0.73 (0.63–
0.84)
0.478 0.021 0.116
8 rs2736332 11,339,965 C/G 0.326/
0.271
1.52 3
1013
1.3 (1.21–
1.4)
0.82 0.31 0.813/
0.735
2.93 3
1011
1.57 (1.37–
1.79)
0.87 0.19 0.599/
0.563
0.005471 1.16 (1.04–
1.28)
0.253 0.724 0.895
8 rs7812879a 11,340,181 G/A 0.856/
0.843
3.35 3
1002
1.1 (1.01–
1.2)
0.07 0.82 0.836/
0.766
4.78 3
1010
1.55 (1.35–
1.79)
0.73 0.33 0.8/0.775 0.01928 1.15 (1.02–
1.3)
0.094 0.166 0.515
8 rs2254891g 11,341,129 C/G 0.712/
0.694
1.29 3
1002
1.09 (1.02–
1.17)
0.16 0.58 0.826/
0.759
2.31 3
1009
1.52 (1.32–
1.75)
0.76 0.68 0.848/
0.828
0.02776 1.16 (1.01–
1.33)
0.061 0.665 0.359
8 rs2736336 11,341,870 G/T 0.699/
0.752
2.19 3
1013
0.76 (0.71–
0.82)
0.94 1.00 0.197/
0.272
4.19 3
1010
0.65 (0.56–
0.75)
0.90 0.87 0.794/
0.838
4.237 3
1006
0.74 (0.65–
0.84)
0.348 0.034 0.096
8 rs2736337 11,341,880 T/C 0.699/
0.752
2.24 3
1013
0.76 (0.71–
0.82)
0.94 0.98 0.197/
0.272
3.96 3
1010
0.65 (0.56–
0.75)
0.89 0.78 0.795/
0.84
2.178 3
1006
0.73 (0.64–
0.83)
0.325 0.024 0.069
8 rs2736338 11,341,883 A/C 0.699/
0.752
2.23 3
1013
0.76 (0.71–
0.82)
0.94 0.98 0.197/
0.272
4.00 3
1010
0.65 (0.56–
0.75)
0.90 1.00 0.795/
0.84
0.00000218 0.73 (0.64–
0.83)
0.325 0.024 0.069
8 rs2254660 11,342,986 G/C 0.859/
0.848
6.63 3
1002
1.09 (0.99–
1.19)
0.07 0.99 0.829/
0.759
9.49 3
1010
1.54 (1.33–
1.77)
0.78 0.60 0.894/
0.876
0.03329 1.19 (1.01–
1.4)
0.030 0.411 0.217
8 rs2254546 11,343,680 G/A 0.855/
0.843
3.37 3
1002
1.1 (1.01–
1.2)
0.07 0.82 0.828/
0.759
1.04 3
1009
1.54 (1.33–
1.77)
0.78 0.66 0.876/
0.858
0.03353 1.17 (1.01–
1.36)
0.045 0.609 0.336
8 chr11343717 11,343,717 A/G / - - - - / - - - - 0.979/
0.97
0.03673 1.4 (1.01–
1.94)
0.014 0.159 0.118
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Table 2. Continued
Chr. dsSNP
BP
(build37)
Allele1/
Allele2
European Americana Asianb African Americanc
Freq_
Allele1
(Case/
Control)d eAdj. p
OR
(95% CI)
r2
Peak
fpcond on
rs998683
Freq_
Allele1
(Case/
Control) Adj. p
OR
(95% CI)
r2
Peak
pcond on
rs1478901
Freq_
Allele1
(Case/
Control) Adj. p
OR
(95% CI)
r2
Peak
pcond on
rs2736345
pcond on
rs922483
8 rs2736340g 11,343,973 G/A 0.7/0.753 2.09 3
1013
0.76 (0.71–
0.82)
0.94 0.89 0.188/
0.265
9.16 3
1011
0.65 (0.56–
0.74)
0.87 0.31 0.824/
0.866
5.323 3
1006
0.73 (0.64–
0.84)
0.481 0.024 0.129
8 rs2618473g 11,344,127 G/A 0.69/
0.743
3.25 3
1013
0.77 (0.71–
0.83)
0.89 0.79 0.189/
0.265
8.64 3
1011
0.65 (0.56–
0.74)
0.87 0.32 0.552/
0.582
0.01564 0.88 (0.8–
0.98)
0.033 0.478 0.258
8 rs4840565g 11,345,545 G/C 0.33/
0.278
8.07 3
1012
1.27 (1.19–
1.37)
0.81 0.98 0.823/
0.754
1.84 3
1009
1.52 (1.32–
1.75)
0.81 0.88 0.36/
0.312
0.00008384 1.23 (1.11–
1.36)
0.529 0.192 0.431
8 rs2736342g 11,347,289 A/C 0.49/
0.448
3.67 3
1007
1.18 (1.11–
1.26)
0.39 0.68 / - - - - 0.556/
0.523
0.00846 1.14 (1.03–
1.26)
0.315 0.868 0.930
8 rs1478900g 11,347,660 A/G 0.854/
0.844
6.64 3
1002
1.09 (0.99–
1.19)
0.07 0.96 0.807/
0.736
1.15 3
1009
1.51 (1.32–
1.73)
0.89 0.30 0.874/
0.857
0.04142 1.16 (1–
1.35)
0.042 0.607 0.343
8 rs1478901g 11,347,833 C/G 0.701/
0.754
2.92 3
1013
0.77 (0.71–
0.82)
0.95 0.99 0.208/
0.29
1.32 3
1011
0.64 (0.56–
0.73)
1.00 - 0.822/
0.864
0.00000525 0.73 (0.64–
0.84)
0.477 0.039 0.140
8 chr11348647 11,348,647 C/A / - - - - / - - - - 0.982/
0.987
0.02851 0.61 (0.39–
0.96)
0.034 0.529 0.530
8 rs9693589 11,348,961 G/A 0.701/
0.754
2.96 3
1013
0.77 (0.71–
0.82)
0.95 1.00 0.212/
0.291
4.15 3
1011
0.65 (0.57–
0.74)
0.94 collinear 0.824/
0.866
5.801 3
1006
0.73 (0.64–
0.84)
0.487 0.024 0.116
8 rs13277113g 11,349,186 G/A 0.701/
0.754
2.98 3
1013
0.77 (0.71–
0.82)
0.95 1.00 0.212/
0.291
4.28 3
1011
0.65 (0.57–
0.74)
0.94 collinear 0.824/
0.866
5.739 3
1006
0.73 (0.64–
0.84)
0.487 0.024 0.116
8 rs9694294g 11,350,721 C/G 0.855/
0.843
4.22 3
1002
1.1 (1–1.2) 0.07 0.93 0.817/
0.747
8.79 3
1010
1.52 (1.33–
1.75)
0.77 0.66 0.839/
0.812
0.004564 1.21 (1.06–
1.38)
0.077 0.369 0.182
8 rs1478902g 11,350,774 A/C / - - - - / - - - - 0.984/
0.977
0.04526 1.44 (0.99–
2.08)
0.016 0.176 0.142
8 rs4840568g 11,351,019 G/A 0.675/
0.73
1.46 3
1013
0.77 (0.71–
0.83)
0.83 0.27 0.208/
0.287
5.67 3
1011
0.65 (0.57–
0.74)
0.91 collinear 0.634/
0.665
0.0106 0.87 (0.79–
0.97)
0.162 0.246 0.597
8 rs922483g 11,351,912 A/G 0.344/
0.291
5.27 3
1012
1.27 (1.19–
1.36)
0.76 0.43 0.807/
0.735
1.06 3
1009
1.51 (1.32–
1.73)
0.83 0.98 0.308/
0.252
1.151 3
1006
1.31 (1.17–
1.47)
1.000 0.069 -
8 chr11351937 11,351,937 G/T / - - - - / - - - - 0.984/
0.977
0.04802 1.44 (0.99–
2.09)
0.016 0.196 0.158
8 rs2250788g 11,352,056 G/A 0.855/
0.843
3.83 3
1002
1.1 (1–1.2) 0.07 0.89 0.818/
0.747
8.27 3
1010
1.53 (1.33–
1.75)
0.76 0.56 0.843/
0.818
0.009211 1.19 (1.04–
1.37)
0.084 0.376 0.222
8 rs13272061g 11,352,261 C/A 0.5/0.459 6.15 3
1007
1.18 (1.1–
1.26)
0.37 0.59 / - - - - 0.862/
0.844
0.04183 1.15 (1–
1.33)
0.071 0.711 0.450
(Continued on next page)
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The AmAfter applying quality-control measures and adjusting for
admixture within and across populations (Figure S1), we
analyzed a total of 6,658 independent cases and 6,550 in-
dependent controls (Table 1 and Table S1).
To enrich the genotyped data set for nongenotyped SNPs,
we imputed variants located between 11,033,737 bp and
11,618,107 bp (hg19) by using population-specific refer-
ence panels derived from the 1000 Genomes Project.22
SNP-association results for each population are shown or
listed in Figures 1A–1C, Table 2, and Table S3). Considering
the correlated variants that had r2> 0.6 with the peak asso-
ciated SNP in each population, we observed 30 SNPs
demonstrating association in the AS population (peak
SNP rs1478901, p ¼ 1.32 3 1011, OR ¼ 0.64, 95% CI ¼
0.56–0.73) and 20 SNPs demonstrating association in the
EA population (peak SNP rs998683, p ¼ 5.22 3 1014,
OR ¼ 0.76, 95% CI ¼ 0.71–0.82) (Table 2). However, we
observed only two associated SNPs (SNP rs2736345, p ¼
1.49 3 106, OR ¼ 1.28, 95% CI ¼ 1.15-1.42 and peak
SNP rs922483, p ¼ 1.15 3 106, OR ¼ 1.31, 95% CI ¼
1.17–1.47) in the AA population because of the reduced
LD in this region. Both variants identified in the AA
population are within the subset of variants that were iden-
tified in the EA and AS samples as having r2 > 0.6 relative
to the peak SNPs, suggesting that the same causal variants
are present in all three populations. Conditional associa-
tion tests performed within each population validated
rs998683, rs1478901, and rs922483 as themain SLE-associ-
ated variant for EA, AS, andAA, respectively (Table 2). Thus,
rs922483 is likely to be the predominant SLE-associated
variant.
We concluded that, of the common associated variants,
rs922483 was the stronger functional candidate given that
it is located near a putative transcript initiator (INR) site23
(Figure S4) in a region predicted to bind RNA polymerase II
(RNAPII), and its association with SLE remained significant
when conditioned on rs2736345 (Table 2).
Resequencing Identified an Additional SLE-Associated
triallelic SNP, rs1382568, Located within the
B-Cell-Specific Promoter
To ensure identification of other uncommon and multi-
allelic genetic variation in this region, we resequenced
all 13 BLK exons and the 2.5 kb upstream promoter
regions in 191 EA SLE individuals and 96 EA controls
from the Autoimmune Biomarkers Collaborative Network
(ABCoN) and the New York Cancer Project (NYCP), respec-
tively. Although no additional nongenotyped or nonim-
puted biallelic variants were detected, an SLE-associated
tri-allelic variant, rs1382568 (A/G/C), that is highly corre-
lated with the variant (rs922483) identified in our trans-
population association study was identified (Table 3 and
Table S3).
To confirm the association of these two variants, we used
data obtained for these two SNPs from additional rese-
quencing efforts on 960 subjects (710 affected individuals
and 250 control individuals). Association analysis resultserican Journal of Human Genetics 94, 586–598, April 3, 2014 591
Figure 1. Genetic Association of SNPs in and around the
FAM167A/BLK Gene Locus in SLE-Affected Individuals
SNPs in and around the FAM167A/BLK gene locus in individuals
with SLE with (A) European ancestry, (B) Asian ancestry (C), and
African American ancestry are shown. All SNPs with an r2 > 0.6
(correlation with previously reported peak SNP rs13277113) are
displayed. The solid blue line represents recombination rates
across the region. The most significantly associated SNP in each
population is colored purple, and the SNP number is indicated.
(D) A schematic with key features of the BLK proximal promoter
is shown. Probe P2 and P1 represent the 100 bp probe flanking
the candidate variants, rs1382568 and rs922483. P2 and common
qPCR products represent the products from luciferase gene-spe-
cific reverse transcription using product-specific primers (repre-
sented by red arrows).
592 The American Journal of Human Genetics 94, 586–598, April 3, 2from these data demonstrate that both C and A alleles at
rs1382568 individually contributed to the increased SLE
risk when compared to the G allele (OR 1.70, p ¼ 4 3
103; and OR 2.53, p ¼ 6.66 3 104, respectively). Associ-
ation analysis using the combined C/A risk allele at
rs1382568 had an OR ¼ 1.90 and p ¼ 6.66 3 104. This
tri-allelic variant is located within the alternative BLK
promoter (P2)1 (Figure 1D). These data, and previously
published results demonstrating that endogenous BLK
expression varies with B cell developmental stage,24 led
us to hypothesize that the SLE-associated P2 variant might
contribute to disease risk by promoting functional
effects in B cells at discrete stages of development. We
functionally characterized both variants (rs1382568 and
rs922483) in B cell lines that phenotypically represent
different stages of B cell development.
Both Risk Alleles at rs922483 (T) and rs1382568 (C)
Alter BLK Transcription
To investigate the impact of the SLE-associated promoter
variants on BLK transcription, we cloned the BLK promoter
region (2256 to þ55 bp) into a firefly luciferase re-
porter vector and performed site-directed mutagenesis to
generate all six possible haplotype combinations of the
rs1382568 (P2) and rs922483 (P1) variants. B lymphoma
cell lines with distinct phenotypes representing various
B cell developmental stages were transfected with the re-
porter constructs. RS4;11 and Nalm-6 cell lines are repre-
sentative of early stages of B cell development (pre- and
pro-B cells), whereas Ramos and Daudi lines represent
more mature B cells. The allelic effects of both BLK pro-
moter variants were also tested in Jurkat cells, which are
phenotypically similar to mature T cells. Endogenous
BLK protein expression in each of these lines was
confirmed to be as previously described (Figure S2).1,12
Because of the small numbers of SLE-affected individuals
carrying both risk alleles P1 and P2, we utilized in vitro
assays to better isolate the influence of the P1 variant on
BLK promoter activity. We assessed the average of lucif-
erase activities of all P1-risk-allele- (T)-containing vectors,
including T(P1)-C(P2), T(P1)-A(P2), and T(P1)-G(P2), as
well as all P1-nonrisk-allele-containing vectors. The risk
allele (T) at the P1 variant resulted in reductions of normal-
ized luciferase expression in mature B (35%, Daudi) and
mature T (32%, Jurkat) cell lines regardless of the allele at
the P2 variant (p value < 0.05) (Figure 2A). The effect of
the risk allele at the P1 variant on BLK-promoter-driven
transcription was less pronounced in RS4;11 (pro-B) and
Nalm-6 (pre-B) cells. Nuclear-factor binding assays demon-
strated that the allelic variants at the P1 site altered
nuclear-factor recruitment to the P1 promoter (Figure S3A),
most likely as a result of changes in either the recruitment
or the affinity of binding of the complement of nuclear fac-
tors and RNA-polymerase-complex components to this re-
gion of the BLK promoter, as suggested by a super-shift
binding assay (Figure S3B). However, the complex nature
of nuclear-factor binding to this site hampered our ability014
Table 3. Analysis Results of Variations Identified in Resequencing within the Noncoding Region of BLK
Genomic
Location
Nucleotide
Change dbSNP
Associated
Allele
Case, Control Ratio
Counts (191, 96) OR (95% CI) p Value
r2 (with
rs13277113)
11,349,576 C>A rs2251056 A 321:61, 150:42 1.47 (0.95–2.28) 0.0819 0.066
11,350,515 C>T rs76610494 T 8:374, 1:191 4.10 (0.51–32.92) 0.1522 0.006
11,350,678 T>C rs2736344 C 329:53, 149:43 1.79 (1.15–2.80) 0.0098 0.072
11,350,721 C>G rs9694294 G 323:59, 149:43 1.58 (1.02–2.45) 0.0398 0.078
11,350,899 T>C rs1382567 T 199:183, 93:99 1.16 (0.82–1.64) 0.4083 0.335
11,351,019 G>A rs4840568 A 125:257, 41:151 1.79 (1.29–2.69) 0.0046 0.852
11,351,220 A>C rs1382568a C 121:261, 38:154 1.88 (1.24–2.85) 0.0027 0.889
11,351,220 A>G rs1382568a A 200:182, 94:98 1.15 (0.81–1.62) 0.4423 0.331
11,351,912 C>T rs922483 T 137:245, 43:149 1.94 (1.30–2.89) 0.001 0.741
11,352,056 A>G rs2250788 G 320:62, 148:44 1.53 (0.99–2.37) 0.0514 0.059
11,366,671 C>T rs115856097 C 274:108, 128:64 1.27 (0.87–1.84) 0.2117 0.037
11,367,037 G>C rs4629826 G 358:24, 176:16 1.36 (0.70–2.62) 0.3626 0.018
11,367,042 C>T rs76154097 T 55:327, 23:169 1.24 (0.73–2.08) 0.4249 0.038
11,367,092 T>C rs2409782 C 91:291, 45:147 1.02 (0.68–1.54) 0.9186 0.001
11,415,571 A>G rs4841557 A 158:222, 63:129 1.46 (1.01–2.10) 0.042 0.187
11,415,596 C>T rs4841558 C 157:223, 63:129 1.44 (1.00–2.08) 0.0484 0.181
11,418,385 G>A rs1042695 A 145:237, 59:133 1.38 (0.95–2.00) 0.0878 0.179
11,418,765 G>A rs368588162 A 335:45, 157:35 1.66 (1.03–2.68) 0.0375 0.019
11,418,766 G>A rs62490888 G 340:42, 157:35 1.81 (1.11–2.94) 0.0164 0.015
11,418,772 C>T rs4841561 T 146:234, 59:133 1.41 (0.97–2.04) 0.07 0.177
11,421,383 C>T rs10097015 T 160:222, 68:122 1.29 (0.90–1.85) 0.1608 0.161
11,421,793 C>T rs1042689 T 144:238, 62:130 1.27 (0.88–1.83) 0.2028 0.161
11,422,045 G>A rs1042701 G 213:169, 98:94 1.21 (0.86–1.71) 0.2845 0.2
11,422,130 T>C rs7843987 T 212:170, 100:92 1.15 (0.81–1.62) 0.4385 0.219
The two SNPs shown in italics (rs1382568* and rs922483) showed association with the loci identified from the GWAS (rs13277113, OR 1.39, p¼ 13 1010, ref.1)
with r2 > 0.5; ars1382568 is a tri-allelic SNP (A/C/G); the C allele was identified as a risk allele.to define the exact molecular interaction affected by the
nucleotide variation at this site.
In order to explore the effect of P2, we compared the
averaged luciferase activities from all vectors containing
the P2 risk allele (C) with other vectors containing the P2
risk allele (C). We observed the most significant allelic
effect at the P2 site in early B cells (RS4;11 and Nalm-6),
where risk alleles A or C at the P2 site reduced luciferase
expression in comparison to the nonrisk allele (G) at this
variant (p value < 0.05) (Figure 2B). However, the impact
of the P2 variant became insignificant when this variant
was transfected into more mature B cell lines. Nuclear-
factor binding assays showed that the risk allele (C)
reduced the binding affinity of multiple nuclear-factor
complexes to the probe containing the P2 allelic variant
(Figure S3C).
The results from these assays demonstrate that the
lupus-associated risk alleles at both the P1 site (rs922483)
and the P2 site (rs1382568) reduce the transcriptionalThe Amactivity of the BLK promoter in vitro. However, the effect
of the risk allele at the P1 site most significantly affects
BLK transcription in more mature B cells, whereas the
effects of the risk alleles at the P2 site most significantly
affect BLK transcription in more immature B cells.
P1 Variant Modulates Promoter Usage
Genes such as BLK that have multiple TSSs (transcription
start sites) represent a class of genes in which changes in
gene expression might be attributed to polymorphisms at
multiple promoter sites. Selection of promoter use can
vary on the basis of the organization of specific nuclear-
factor binding sites and/or the epigenetic conformation
of the genomic DNA in the promoters surrounding these
TSSs. In addition, the organization of the promoters and/
or TSSs and the dynamics of the transcription initiation
and elongation steps of the RNA polymerase from each
promoter influence which transcripts predominate within
a cell. Differential promoter and TSS usage has beenerican Journal of Human Genetics 94, 586–598, April 3, 2014 593
Figure 2. Both P1 and P2 Variants Affect BLK-Promoter-Driven
Transcriptional Activity
Mean and standard error of measure (SEM) are displayed in the
center, and probability density functions are represented by the
sides. The effect of P1 variant with either risk or nonrisk P2 haplo-
type on overall luciferase expression (A) and the transcriptional
activity in cell lines transfected with reporter vectors carrying
one of the three SLE-associated P2 variants with a nonrisk P1 (B)
is shown. Nine transfections of each vector carrying the P1 allele
being compared were performed in each model cell line (n ¼ 9),
and triplicates were assessed for luciferase activity to give normal-
ized means for each transfection. P1 risk [R(T)] and nonrisk
[NR(C)] variants are compared (mean 5 SEM). P2 variants of
each allele (G, A, or C) were assessed in six experiments. Normal-
ized luciferase ratio ¼ (normalized luciferase activity of the haplo-
type)/(normalized luciferase activity of the T allele at P1  the
luciferase activity of the C allele at P2). The normalized luciferase
activity for the haplotype ¼ luciferase activity of BLK:pGL4/lucif-
erase activity of TK:pRL. *p < 0.05 in a paired t test. Means5 SEM
are shown.
Figure 3. P1 Variant Altered Promoter Usage in RS4;11 and
Nalm-6 Cell Lines
Percentages of the total BLK promoter-luciferase derived tran-
scripts initiated from the P2 were determined using gene-specific
RT-qPCR 16 hr post-transfection. *p-value < 0.05 using paired
t test. Mean5 SEM are shown.elegantly demonstrated in the regulation of expression of
the human c-myc gene (MIM 190080).25 In this case, a
preferred downstream promoter normally impedes (atten-
uates) the transcription initiated from the upstream
promoter. However, inhibition of binding of the transcrip-
tionalmachinery (e.g., RNA polymerase complex) prevents
transcription initiation at the downstream c-myc pro-
moter, removing attenuation of the upstream promoter
and resulting in the upstream promoter’s becoming the
preferred promoter.
To determine whether such a mechanism controls BLK
promoter selection and whether lupus-disease-associated
variants in the BLK promoter P1 site can alter this mecha-
nism, we used a transcript-specific luciferase reporter RT-
qPCR assay to quantitate the percentage of the total BLK
reporter transcripts in the B cell panel representing various
cell stages of development. The usage of P2 and TSS2 was
significantly higher in a majority of the B cell lines than594 The American Journal of Human Genetics 94, 586–598, April 3, 2in the mature T (Jurkat) cell line (p < 0.05) (Figure 3).
This finding is consistent with the observations made by
Lin et.al.,1 who showed that the P2 promoter is primarily
used by B cells. The risk allele (T) at the P1 variant reduced
the P1 and TSS1 contribution to the overall BLK-luciferase-
reporter transcript levels in all cells, independent of the P2
variant (p < 0.05) (Figure 2A). However, the usage of P2
and TSS2 was increased by 21% and 12% in the immature
B cell lines (RS4;11 and Nalm-6, respectively) in the pres-
ence of a risk-allele (T) at the P1 variant (Figure 3). These
results suggest that lupus-associated risk alleles at the P1
variant decrease the effective initiation of the BLK-reporter
transcription from P1 and TSS1. This might lower the
attenuation of P2 and TSS2 in early B cells, presumably
by a mechanism similar to that observed with the c-myc
gene. These findings provide mechanistic insights as to
how multiple disease-associated variants in different pro-
moters can have a collective effect modulating expression
of disease-associated genes.Discussion
Previous studies have linked multiple genetic variants at
many loci with the development of autoimmune dis-
ease.26–31 Genetic variants found at the FAM167A/BLK
locus are associated with multiple autoimmune diseases,
including SLE, systemic sclerosis, rheumatoid arthritis,
and Sjo¨gren’s syndrome.4–11 Although risk-conferring var-
iants within FAM167A/BLK have been shown to be associ-
ated with altered mRNA expression of both FAM167A and
BLK,7 the causal allele or alleles remain undefined as a
result of the strong association between potential causal
alleles and noncausal variants. Using the trans-population
mapping and sequencing strategy, we focused on two com-
mon associated variants (rs922483 and rs1382568) located014
within the two promoter regions of BLK for additional
functional analysis.
Previously published data defined the two BLK pro-
moters and TSSs as a ubiquitously expressed TSS1 and a
B cell-specific TSS2 located approximately 400 bp upstream
of the ubiquitous promoter.1 Because both candidate
lupus-associated variants were located in functionally
important loci of the BLK promoter, we hypothesized
that they might alter unique aspects of BLK transcriptional
regulation. The rs922483 SNP resides in the ubiquitous
P1 and TSS1 site within a putative initiator of transcription
(INR) site.23 The other lupus-associated variant, rs1382568,
is located in an upstream P2 region that is highly enriched
for several B-cell-specific nuclear-factor binding sites.
Because rs922483 and rs1382568 have a high degree of
association with SLE and are located in key regions of pro-
moters, our results confirm the possibility that these vari-
ants contribute to disease development through regulation
of BLK promoter activity.
We used reporter assays and nuclear-factor binding in
B cell lines with phenotypes representative of different
developmental stages to study the effects of variants on
promoter activity. We cannot exclude the possibility that
fresh B cells might behave differently; it is possible that pri-
mary lymphocytes might have different expression levels
and activity levels of transcription factors and that these
different levels might result in altered BLK transcription
not observed in cell lines. However, our data directly
compared the effects of promoter alleles within various
types of developmental stages of B cell lines characterized
to represent different stages of B cell development to give
a clearer picture of BLK transcription in early B cell devel-
opment. Isolating sufficient numbers of primary progeni-
tor B cells with all haplotypes would be prohibitive.
Despite its limitations, this reporter assay allowed assess-
ment of both the allelic and haplotype effects of these
variants on BLK promoter activity within multiple repre-
sentative cell types.
Our results demonstrated that both variants play a role
in regulating BLK transcription. Risk alleles at these sites
most likely alter the affinity and/or specificity of binding
of critical nuclear factors and their interactions with RNA
polymerase II subunits. Our results indicate that the degree
of impact of a particular risk allele on BLK transcription de-
pends both upon cell type and, in the cases of B cells, upon
the developmental stage. This is consistent with observa-
tions made by Simpfendorfer et.al. in primary cells, where
they reported that a risk allele at rs922483 (P1 variant) led
to an overall reduction in BLK mRNA expression in T cells
from human peripheral-blood and umbilical-cord B cells.12
Although the transcription of BLK was affected by the
variant in early B and T cells, BLK protein level was only
significantly reduced in umbilical-cord B cells.12
On the basis of our results and the previously published
information, we propose a molecular mechanistic model
depicting the cell-type- and developmental-stage-specific
effect of both lupus-associated variants on the overallThe AmBLK promoter activity (Figure 4A). In this model, the P1
promoter is the predominant promoter. When the RNA
polymerase II complex binds and initiates transcription
from this promoter, the P2 B-cell-specific promoter is
stochastically inhibited or P2-initiated transcription is
prematurely terminated by RNA polymerase complexes
bound to the P1 site. Because P1 is the only active pro-
moter in non-B cells, a switch to a risk allele at the P1
site alone will lead to a significant reduction in overall
BLK promoter activity.
Alternatively, in B cells, production of BLK transcripts
would be derived from both the P1 and TSS1 site and the
P2 and TSS2 site. In mature B cells, P1 and TSS1 remain
the preferred promoters, possibly as a result of nuclear fac-
tors and chromatin conformation at that site, which favor
high-affinity RNA polymerase II binding and transcription
from P1 and TSS1. When a lupus risk allele is present at the
P1 site, possibly lowering the affinity of nuclear factor
binding or efficiency of RNA polymerase transcription
initiation, the obstruction and attenuation of P2 initiated
transcription would be diminished resulting in more P2
derived transcripts. In this environment, an additional
risk allele at the P2 site would result in altered nuclear-
factor binding and RNA-polymerase-complex binding
and initiation of transcription from this promoter. From
this model, one would predict that the most dramatic
decrease in BLK expression in immature B cells would
occur when risk alleles were found at both the P1 and P2
sites and that this would result in increased risk for devel-
oping lupus.
Information accumulated from this and other studies is
beginning to shape our overall understanding of how var-
iations in BLK transcription expression and BLK protein
levels contribute to development and/or progression of
lupus.2,3,12,32 The emerging picture suggests that the varia-
tion of BLK expression is likely to result in varying
functional consequences at different stages of B cell devel-
opment and in different cell types (Figure 4B). Reduction
in BLK expression by risk haplotypes could directly affect
B lymphocyte development and/or impair functional re-
sponses in B cells early in development. Indeed, several
previously published results indicate that the knockout
of one allele of Blk leads to increased splenic marginal
zone and peritoneal B1 B cells in older mice,3 suggesting
a regulatory role for BLK. Because BLK is capable of inter-
acting with both pre-B cell receptors and mature B cell
receptors, it could play a critical role in regulating B cell
selection and immune responses. Recently, BLK has also
been shown to enhance BANK1 (MIM 610292) and
PLCg1 (MIM 172420) interactions upon BCR activation
to modulate B cell responses.33 Other lupus-associated
risk alleles in coding SNPs of BLK have been shown to
result in reduced BLK protein stability.10 In addition, BLK
deficiency can impair early T cell development as well as
the development of IL-17-producing gd T cells.2 Although
there has been a suggestion that BLK is also an important
signal transduction molecule in plasmacytoid dendriticerican Journal of Human Genetics 94, 586–598, April 3, 2014 595
Figure 4. Proposed Molecular Model of Transcriptional Control of BLK Expression
A proposedmodel depicting how the lupus-associated risk alleles at the P1 and P2 sites alter BLK transcription (A) and a proposed model
representing ways in which BLK might affect B cell development and control of autoimmune responses (B) are shown.cells (pDCs), further investigations are necessary for the
evaluation of the association between BLK-related alter-
ations in pDCs and autoimmune diseases.34 Our results
indicate that BLK risk alleles alter BLK promoter activity
and might thus contribute to autoreactive or regulatory
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